176 related articles for article (PubMed ID: 27747005)
21. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
[TBL] [Abstract][Full Text] [Related]
22. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
23. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
[TBL] [Abstract][Full Text] [Related]
24. Pro-gastrin-releasing peptide in patients with benign and malignant diseases.
Molina R; Auge JM; Alicarte J; Filella X; Viñolas N; Ballesta AM
Tumour Biol; 2004; 25(1-2):56-61. PubMed ID: 15192313
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of chemiluminescent immunoassay quantitative detection for pro-gastrin-releasing peptide (ProGRP) in serum and plasma.
Cheng Y; He J; Zhang L; Chen X; Ou S
J Int Med Res; 2020 Apr; 48(4):300060519882802. PubMed ID: 31856626
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of ProGRP for small cell lung cancer in different stages.
Dong A; Zhang J; Chen X; Ren X; Zhang X
J Thorac Dis; 2019 Apr; 11(4):1182-1189. PubMed ID: 31179060
[TBL] [Abstract][Full Text] [Related]
27. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
28. ProGRP AS A NOVEL BIOMARKER FOR THE DIFFERENTIAL DIAGNOSIS OF MEDULLARY THYROID CARCINOMA IN PATIENTS WITH THYROID NODULES.
Liang X; Zhu J; Cai M; Dai Z; Fang L; Chen H; Yu L; Lin Y; Lin E; Wu G
Endocr Pract; 2020 May; 26(5):514-522. PubMed ID: 32045291
[No Abstract] [Full Text] [Related]
29. New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.
Nisman B; Nechushtan H; Biran H; Peled N; Gantz-Sorotsky H; Doviner V; Perelman M; Bar J; Onn A; Uziely B; Peretz T
Br J Cancer; 2016 Feb; 114(4):469-76. PubMed ID: 26812573
[TBL] [Abstract][Full Text] [Related]
30. Clinical Application of Pro-Gastrin-Releasing Peptide.
Fang L; Huang Z; Lin Y; Fu J; Liang X; Liu F
Clin Lab; 2018 Jul; 64(7):1259-1268. PubMed ID: 30146822
[TBL] [Abstract][Full Text] [Related]
31. Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm.
Rosiek V; Kogut A; Kos-Kudła B
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444393
[TBL] [Abstract][Full Text] [Related]
32. Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer.
Rupp A; Bahlmann S; Trimpop N; von Pawel J; Holdenrieder S
Tumour Biol; 2024; 46(s1):S341-S353. PubMed ID: 37545291
[TBL] [Abstract][Full Text] [Related]
33. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
Takada M; Kusunoki Y; Masuda N; Matui K; Yana T; Ushijima S; Iida K; Tamura K; Komiya T; Kawase I; Kikui N; Morino H; Fukuoka M
Br J Cancer; 1996 May; 73(10):1227-32. PubMed ID: 8630283
[TBL] [Abstract][Full Text] [Related]
34. Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31-98) as tumor marker for small-cell lung carcinoma: development and evaluation.
Aoyagi K; Miyake Y; Urakami K; Kashiwakuma T; Hasegawa A; Kodama T; Yamaguchi K
Clin Chem; 1995 Apr; 41(4):537-43. PubMed ID: 7720242
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations.
Kudo K; Ohyanagi F; Horiike A; Miyauchi E; Yanagitani N; Hoshi R; Satoh Y; Motoi N; Hamanaka W; Ishikawa Y; Mun M; Sakao Y; Okumura S; Nakagawa K; Horai T; Nishio M
Lung Cancer; 2011 Dec; 74(3):401-4. PubMed ID: 21529988
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer.
Naumnik W; Chyczewska E; Izycki T; Ossolinska M
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():88-90. PubMed ID: 15638385
[TBL] [Abstract][Full Text] [Related]
37. Development and analytical performance evaluation of an automated chemiluminescent immunoassay for pro-gastrin releasing peptide (ProGRP).
Yoshimura T; Fujita K; Kinukawa H; Matsuoka Y; Patil RD; Beligere GS; Chan SS; Dowell BL; Sokoll L; Elliott D; Chan DW; Scheuer C; Hofmann K; Stieber P; Sakurai Y; Iizuka M; Saegusa H; Yamaguchi K
Clin Chem Lab Med; 2009; 47(12):1557-63. PubMed ID: 19824798
[TBL] [Abstract][Full Text] [Related]
38. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
39. Instability of Plasma and Serum Progastrin-Releasing Peptide During Repeated Freezing and Thawing.
Lee JE; Lee JH; Hong M; Park SK; Yu JI; Shin SY; Kim SY
Osong Public Health Res Perspect; 2016 Dec; 7(6):351-355. PubMed ID: 28053839
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
